<code id='FF8E056479'></code><style id='FF8E056479'></style>
    • <acronym id='FF8E056479'></acronym>
      <center id='FF8E056479'><center id='FF8E056479'><tfoot id='FF8E056479'></tfoot></center><abbr id='FF8E056479'><dir id='FF8E056479'><tfoot id='FF8E056479'></tfoot><noframes id='FF8E056479'>

    • <optgroup id='FF8E056479'><strike id='FF8E056479'><sup id='FF8E056479'></sup></strike><code id='FF8E056479'></code></optgroup>
        1. <b id='FF8E056479'><label id='FF8E056479'><select id='FF8E056479'><dt id='FF8E056479'><span id='FF8E056479'></span></dt></select></label></b><u id='FF8E056479'></u>
          <i id='FF8E056479'><strike id='FF8E056479'><tt id='FF8E056479'><pre id='FF8E056479'></pre></tt></strike></i>

          hotspot

          hotspot

          author:entertainment    Page View:394
          Adobe

          By some measures, private equity investment lagged in 2023, a year marked by growing distress and high-profile downfalls among private equity-backed health care companies.

          Even so, three sectors still managed to see strong deal flow and prices: med spa, cardiology, and clinical trial sites, according to a new PitchBook report analyzing private equity investments in health care services in 2023. Each of the three niches continue to generate buzz among investors, even as other areas fizzle.

          advertisement

          It’s not that those three industries are perfect fits for private equity, it’s that the more obvious areas like autism therapists and physician practices are struggling with high interest rates and regulatory scrutiny, said Rebecca Springer, PitchBook’s lead health care analyst.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more
          Albert Bourla of Pfizer: worst biopharma CEO of 2023
          Albert Bourla of Pfizer: worst biopharma CEO of 2023

          HyacinthEmpinado/STATPfizeristhisyear’santi-EliLilly.IfDavidRicksisthebestbiopharmaCEOof2023,thenPfi

          read more
          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more

          Hospitals owned by private equity see complications spike 25%

          AdobeThere’sampleevidencethatprivateequitybuyoutsinhealthcaredriveupcosts.Anewstudyshowsqualitydecli